Zydus Lifesciences share price extended the gains on second day, rising 1 percent in the early trade on April 15 following United States Food and Drug Administration (USFDA) approval for Jaythari (Deflazacort) tablets.
At 09:21am, Zydus Lifesciences was quoting at Rs 878.05, up Rs 9.80, or 1.13 percent, on the BSE.
The drug maker will produce Jaythari (Deflazacort) 6 mg, 18 mg, 30 mg and 36 mg tablets at Doppel Farmaceutici S.r.l., Italy facility, company said in exchange filing.
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.
The group now has 424 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.
Catch all the market action on our live blog
Zydus MedTech, a wholly owned subsidiary of the company has incorporated a wholly owned subsidiary in the name of Zydus MedTech (France) SAS on April 10, 2025.
The share touched a 52-week high of Rs 1,323.90 and a 52-week low of Rs 797.05 on 09 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 33.68 percent below its 52-week high and 10.16 percent above its 52-week low.
Market capitalisation stands at Rs 88,352.38 crore.9 months.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
